^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Isocel (ALEXIS-ISO-1)

    i
    Other names: Allogenic Iso-mesotheline MPM/Pleural mets Gamma-Delta-T cells, KB-ISM, Alexis ISO-1, KB-ISO, Alexis Iso-Mesothelin Gamma-Delta-T cells, Alexis Iso-Mesothelin EOC Gamma-Delta-T cells, Alexis Iso-Mesothelin MPM/Pleural mets Gamma-Delta-T cells, ALEXIS-ISO-1, Allogenic Iso-mesotheline EOC Gamma-Delta-T cells, Alexis Iso-Mesothelin MPM Gamma-Delta-T cells , Alexis Allogenic / Iso-Mesothelin MPM/Pleural mets γδ-T cells , Allogenic Iso-mesotheline MPM/Pleural mets Gamma-Delta-T cells, Alexis Allogenic / Iso-Mesothelin EOC γδ-T cells
    Associations

    News

    Trials
    Company:
    Kiromic
    Drug class:
    γδ TCR modulator, Iso-mesothelin-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    Impact of Response to Systemic Bridging Therapy on Clinical Outcomes and Cytokine Profiles in Patients Receiving CD19- CAR T-Cell Therapy for B-Cell Lymphoma (ASH 2023)
    BT was classified as Polatuzumab (pola) based, intensive chemotherapy, lenalidomide/ Bruton tyrosine kinases inhibitors (len/BTKi), or others...Among all pts, 86 (47%) received Axicel, 49 (27%) Tisacel, 36 (20%) Lisocel and, 11 (6%) Brexucel... Our findings suggest that achieving a response to BT is associated with reduced tumor burden and inflammatory markers pre-LD, reflecting inherent disease biology and treatment-refractoriness. Further studies are required to evaluate which BT strategies may optimize the inflammatory cytokine environment for improved outcomes after CD19 CAR T cell therapy.
    Clinical • Clinical data • CAR T-Cell Therapy • IO biomarker
    |
    IL6 (Interleukin 6)
    |
    LDH elevation
    |
    lenalidomide • Yescarta (axicabtagene ciloleucel) • Polivy (polatuzumab vedotin-piiq) • Isocel (ALEXIS-ISO-1)